1. Home
  2. KALV vs LZM Comparison

KALV vs LZM Comparison

Compare KALV & LZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • LZM
  • Stock Information
  • Founded
  • KALV N/A
  • LZM 2021
  • Country
  • KALV United States
  • LZM Isle of Man
  • Employees
  • KALV N/A
  • LZM 177
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • LZM Metal Mining
  • Sector
  • KALV Health Care
  • LZM Basic Materials
  • Exchange
  • KALV Nasdaq
  • LZM Nasdaq
  • Market Cap
  • KALV 523.1M
  • LZM 563.7M
  • IPO Year
  • KALV N/A
  • LZM N/A
  • Fundamental
  • Price
  • KALV $11.18
  • LZM $6.98
  • Analyst Decision
  • KALV Strong Buy
  • LZM Strong Buy
  • Analyst Count
  • KALV 4
  • LZM 2
  • Target Price
  • KALV $29.00
  • LZM $12.50
  • AVG Volume (30 Days)
  • KALV 247.5K
  • LZM 83.3K
  • Earning Date
  • KALV 12-05-2024
  • LZM 11-22-2024
  • Dividend Yield
  • KALV N/A
  • LZM N/A
  • EPS Growth
  • KALV N/A
  • LZM N/A
  • EPS
  • KALV N/A
  • LZM N/A
  • Revenue
  • KALV N/A
  • LZM $1,020,728.00
  • Revenue This Year
  • KALV N/A
  • LZM $5.97
  • Revenue Next Year
  • KALV $539.64
  • LZM $28.67
  • P/E Ratio
  • KALV N/A
  • LZM N/A
  • Revenue Growth
  • KALV N/A
  • LZM N/A
  • 52 Week Low
  • KALV $7.21
  • LZM $4.52
  • 52 Week High
  • KALV $16.88
  • LZM $10.74
  • Technical
  • Relative Strength Index (RSI)
  • KALV 46.78
  • LZM 64.31
  • Support Level
  • KALV $10.78
  • LZM $6.28
  • Resistance Level
  • KALV $12.12
  • LZM $7.17
  • Average True Range (ATR)
  • KALV 0.72
  • LZM 0.33
  • MACD
  • KALV -0.07
  • LZM 0.09
  • Stochastic Oscillator
  • KALV 41.20
  • LZM 86.13

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises two segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary.

Share on Social Networks: